July 08, 2024
1 min watch
Save
VIDEO: Study examines commercial database for selection of patients with prostate cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of transcriptomic signatures to aid in selection of patients with prostate cancer, presented at ASCO Annual Meeting.
Chehrazi-Raffle, a medical oncologist at the City of Hope Duarte Cancer Center, examined a University of California San Diego study into a commercial database that will be incorporated into the upcoming PREDICT trial.
“There's still much more to come down the road, which is a big win for patients, as these more personalized therapies can offer superior efficacy compared to the mutational agnostic options,” Chehrazi-Raffle said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Chehrazi-Raffle reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.